Cambridge Life Sciences Limited, a privately owned company

ELY, Cambridgeshire, January 2004 Cambridge Life Sciences Ltd are pleased to announce that at the end of 2003, the management of Cambridge Life Sciences (CLS) has purchased 100% of the shares from the former parent company ALTANA Pharma AG. The divestment by ALTANA Pharma was driven by its intention to concentrate on its core pharmaceutical business. The deal will permit CLS to expand its key position in the Autoimmune kit market as well as continue to develop its propriety positions in immunosensors and nanotechnology for use in rapid screening kits.

The team, led by Managing Director Mr Peter Blake, has nearly 40 years combined experience in the Diagnostics Industry, and is in a unique position to take Cambridge Life Sciences forward through the next stages of expansion and growth. The company specialises in the Development, Production and Marketing of Autoimmune Diagnostic tests, as well as supplying the majority of the UK requirements for Paracetamol overdose test kits from its home base north of Cambridge.

Managing Director Peter Blake comments "Having been one of the original companies founded as part of the Cambridge Phenomenon we are excited by the prospect of putting Cambridge Life Sciences back on the Cambridge and UK map".

Cambridge Life Sciences will continue to invest in Research and Development, both in their core areas of expertise as well as in their proprietary Biosensor and Immunosensor Technologies. The company is also keen to grow its partnerships and university collaborations in the area of nanotechnology.